Tetrahydrocannabinolic Acid (THC-a) Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 56 studies associated with Tetrahydrocannabinolic Acid (THC-a).
Here is a small sampling of Tetrahydrocannabinolic Acid (THC-a) studies by title:
- Evaluation of the Possible Anticonvulsant Effect of Δ 9-Tetrahydrocannabinolic Acid in Murine Seizure Models
- Modulation of Recombinant Human T-Type Calcium Channels by Δ 9-Tetrahydrocannabinolic Acid In Vitro
- Synthetic Strategies for Rare Cannabinoids Derived from Cannabis sativa
- Modulation of type 1 cannabinoid receptor activity by cannabinoid by-products from Cannabis sativa and non-cannabis phytomolecules
- Fighting the storm: could novel anti-TNFα and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19?
Components of the Tetrahydrocannabinolic Acid (THC-a) Research Dashboard
- Top medical conditions associated with Tetrahydrocannabinolic Acid (THC-a)
- Proven effects in clinical trials for Tetrahydrocannabinolic Acid (THC-a)
- Receptors associated with Tetrahydrocannabinolic Acid (THC-a)
- Individual study details for Tetrahydrocannabinolic Acid (THC-a)
Ready to become a subscriber? Go to our PRICING page.
Page Quick Links
Select New Cannabinoid
Overview - Tetrahydrocannabinolic Acid (THC-a)
Description of Tetrahydrocannabinolic Acid (THC-a)
Delta 9-Tetrahydrocannabinolic Acid (Delta-9-THC-A) was discovered in 1969. It is the precursor to THC the primary psychoactive phytocannabinoid.
Other Names:
Delta 9-Tetrahydrocannabinolic Acid9-carboxy-THC, THC-9-COOH, 9-Carboxy-delta(9)-thc plus numerous other supplier-based synonyms.
IUPAC Name: (6aR,10aR)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid
Molecular Formula: C22H30O4
Source–PubChem
Tetrahydrocannabinolic Acid (THC-a) Properties and Effects
THCA may be:
- Absorbed better systemically than THC (M. Hannon et al., 2020)
- Prevents metabolic disease caused by diet-induced obesity (B. Palomares et al., 2020)
- Anti-inflammatory in animal model of IBD (R. Nallathambi et al., 2017)
- THCA reduce nausea/vomiting (E. Rock et al., 2020; E. Rock et al., 2013)
- Protects dopaminergic neurons against MPP(+) induced cell death (R. Moldzio et al., 2012)
- Potentially immuno-modulating but not via CB1 or CB2 (K. Verhoeckx et al., 2006)
- Neuroprotective (X. Nadal et al., 2017)
Tetrahydrocannabinolic Acid (THC-a) Receptor Binding
Endocannabionoid System (ECS) and THC-A:
- CB1 extremely weak agonism with a Ki of 3.1μM (J. McPartland et al., 2017)
- CB2 extremely weak agonism with a Ki of 12.5μM (J. McPartland et al., 2017)
Ki is typically measure in the nM range or one billionth. In this case efficacy was measured in μM or one millionth. The reader is reminded that the smaller the Ki the stronger the efficacy.
Other trials suggest mixed results indicating possible tissue specific activation (i.e. positive agonism at peripheral CB1 but not central CB1 activation) (X. Nadal et al., 2017)
Endocannabionoidome (eCBome) and THC-A:
- Reduced conductivity of T-type calcium channels (S. Mirlohi et al., 2022)
- Alleviates liver fibrosis and inflammation in mice (B. Carmona-Hidalgo et al., 2021)
- PPARγ potent agonist (X. Nadal et al., 2017)
Ki legend:
- Full/strong agonist Ki ~1-9nM
- Moderate agonist Ki ~10-99nM
- Weak agonist Ki ~100-999nM
- Very weak agonist Ki ~1,000-up nM
(The reader is reminded that a smaller Ki is associated with the strongest effects.)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.
